Glutaminase Inhibitor CB-839

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, Vanderbilt-Ingram Cancer Center

Conditions

Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White CellsChronic Myelomonocytic LeukemiaColorectal CancerHigh Risk Myelodysplastic SyndromeIPSS Risk Category Intermediate-2Metastatic Colorectal Cancer

Phase 1

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

CompletedNCT03047993

M.D. Anderson Cancer CenterAcute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells +4

Start: 2017-11-15End: 2023-03-16Updated: 2024-05-14

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

CompletedNCT03263429

Vanderbilt-Ingram Cancer CenterColorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer +1

Start: 2017-08-23End: 2023-12-21Updated: 2024-08-30

Related Papers

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.

2024-09-1923 citations

AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis

Blood2020-11-044 citations

Abstract 4260: Molecular imaging of glutamine (Gln) metabolism in RAS wildtype (WT) metastatic colorectal cancer (mCRC)

Cancer Research2020-08-153 citations

Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).

Journal of Clinical Oncology2019-05-208 citations

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.

Journal of Clinical Oncology2019-01-295 citations

Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype (WT) colorectal cancer: A phase I/II study.

Journal of Clinical Oncology2018-05-20